Tanespimycin: the opportunities and challenges of targeting heat shock protein 90

Bibliography

• Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008;283:18473-7
   PubMed Web of Science ®Google Scholar
• Pratt WB, Morishima Y, Osawa Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 2008;283:22885-9
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271-94
   PubMed Web of Science ®Google Scholar
• da Rocha Dias S, Friedlos F, Light Y, et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005;65:10686-91
   PubMed Web of Science ®Google Scholar
• Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006;103:57-62
   PubMed Web of Science ®Google Scholar
• Chadli A, Bouhouche I, Sullivan W, et al. Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. Proc Natl Acad Sci USA 2000;97:12524-9
   PubMed Web of Science ®Google Scholar
• Prodromou C, Panaretou B, Chohan S, et al. The ATPase cycle of Hsp90 drives a molecular ‘clamp’ via transient dimerization of the N-terminal domains. Embo J 2000;19:4383-92
   PubMed Web of Science ®Google Scholar
• Available from: htpp://www.picard.ch/downloads/HSP90interactors.pdf.
   Google Scholar
• Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10
   PubMed Web of Science ®Google Scholar
• Shamovsky I, Nudler E. New insights into the mechanism of heat shock response activation. Cell Mol Life Sci 2008;65:855-61
   PubMed Web of Science ®Google Scholar
• Xiao H, Perisic O, Lis JT. Cooperative binding of Drosophila heat shock factor to arrays of a conserved 5 bp unit. Cell 1991;64:585-93
   PubMed Web of Science ®Google Scholar
• Guettouche T, Boellmann F, Lane WS, Voellmy R. Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem 2005;6:4
   PubMedGoogle Scholar
• Arya R, Mallik M, Lakhotia SC. Heat shock genes: integrating cell survival and death. J Biosci 2007;32:595-610
   PubMed Web of Science ®Google Scholar
• Arrigo AP. The cellular ‘networking’ of mammalian Hsp27 and its functions in the control of protein folding, redox state and apoptosis. Adv Exp Med Biol 2007;594:14-26
   PubMed Web of Science ®Google Scholar
• Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-82
   PubMed Web of Science ®Google Scholar
• Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87
   PubMed Web of Science ®Google Scholar
• Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-93
   PubMed Web of Science ®Google Scholar
• Solit DB, Egorin M, Valentin G, et al. Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin). ASCO Meeting Abstracts 2004;22:3032
   Google Scholar
• Musquire LA, Ramalingam S, Egorin MJ, et al. Phase I and pharmacokinetic (PK) study of 17-allylamino-17 demethoxygeldanamycin (17-AAG) in combination with weekly paclitaxel for advanced solid malignancies. ASCO Meeting Abstracts 2007;25:14028
   Google Scholar
• Arlander SJ, Eapen AK, Vroman BT, et al. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7
   PubMed Web of Science ®Google Scholar
• Haluska P, Toft DO, Steinmetz SM, et al. A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients. ASCO Meeting Abstracts 2004;22:3058
   Google Scholar
• Tse AN, Klimstra DS, Gonen M, et al. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 2008;14:6704-11
   PubMed Web of Science ®Google Scholar
• Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-7
   PubMed Web of Science ®Google Scholar
• Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-13
   PubMed Web of Science ®Google Scholar
• Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2. Clin Cancer Res 2005;11:6382-9
   PubMed Web of Science ®Google Scholar
• Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-35
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91
   PubMed Web of Science ®Google Scholar
• Mendelson D, Saif MW, Erlichman C, et al. Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. AACR Meeting Abstracts 2006;47:683
   Google Scholar
• Zhang H, Chung D, Yang YC, et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006;5:1256-64
   PubMed Web of Science ®Google Scholar
• Eiseman JL, Guo J, Weinbaum B, et al. Evaluation of plasma insulin-like growth factor binding protein 2 (IGFBP-2) as a biomarker for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients (pts) with advanced solid tumors. ASCO Meeting Abstracts 2005;23:2083
   Google Scholar
• Banerji U, Affolter A, Judson I, et al. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 2008;7:737-9
   PubMed Web of Science ®Google Scholar
• Ronnen EA, Kondagunta GV, Ishill N, et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543-6
   PubMed Web of Science ®Google Scholar
• Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008;14:7940-6
   PubMed Web of Science ®Google Scholar
• Richardson PG, Chanan-Khan AA, Alsina M, et al. Safety and activity of KOS-953 in patients with relapsed refractory Multiple Myeloma (MM): interim results of a phase 1 trial. ASH Annual Meeting Abstracts. Blood 2005;106:361
   Google Scholar
• Price JT, Quinn JM, Sims NA, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005;65:4929-38
   PubMed Web of Science ®Google Scholar
• Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006;103:17408-13
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Morgan JA, Chugh R, et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. ASCO Meeting Abstracts 2008;26:10503
   Google Scholar
• Sequist L, Janne P, Walker J, et al. Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status. AACR Meeting Abstracts 2007;2007:B79
   Google Scholar
• Ramanathan R, Egorin M, Erlichman C, et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (HSP90), in patients with advanced solid tumors: final results. AACR Meeting Abstracts 2007;2007:B212
   Google Scholar
• Elfiky A, Saif MW, Beeram M, et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. ASCO Meeting Abstracts 2008;26:2503
   Google Scholar
• Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against Xenograft tumor growth, angiogenesis, and metastasis 10.1158/0008-5472.CAN-07-5256. Cancer Res 2008;68:2850-60
   PubMed Web of Science ®Google Scholar
• Bryson JC, Infante JR, Ramanathan RK, et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. ASCO Meeting Abstracts 2008;26:14613
   Google Scholar
• Thompson N, Lyons J, Chessari G, et al. Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines. AACR Meeting Abstracts 2007;2007:5641
   Google Scholar
• McCollum AK, TenEyck CJ, Sauer BM, et al. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 2006;66:10967-75
   PubMed Web of Science ®Google Scholar
• Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14:250-62
   PubMed Web of Science ®Google Scholar
• McCollum AK, TenEyck CJ, Stensgard B, et al. P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 2008;68:7419-27
   PubMed Web of Science ®Google Scholar
• Chin KV, Tanaka S, Darlington G, et al. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990;265:221-6
   PubMed Web of Science ®Google Scholar
• Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2008;68:1188-97
   PubMedGoogle Scholar
• McCollum AK, Lukasiewicz KB, Teneyck CJ, et al. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 2008;7:3256-64
   PubMed Web of Science ®Google Scholar
• Westerheide SD, Kawahara TL, Orton K, Morimoto RI. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006;281:9616-22
   PubMed Web of Science ®Google Scholar
• Koishi M, Yokota S, Mae T, et al. The effects of KNK437, a novel inhibitor of heat shock protein synthesis, on the acquisition of thermotolerance in a murine transplantable tumor in vivo. Clin Cancer Res 2001;7:215-9
   PubMed Web of Science ®Google Scholar